Market Closed -
Nasdaq
04:00:00 2024-07-05 pm EDT
|
5-day change
|
1st Jan Change
|
0.0909
USD
|
-0.11%
|
|
-6.39%
|
-95.71%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
12.63
|
25.23
|
29.17
|
12.86
|
17.92
|
6.388
|
-
|
Enterprise Value (EV)
1 |
12.63
|
25.23
|
29.17
|
12.86
|
17.92
|
6.388
|
6.388
|
P/E ratio
|
-0.72
x
|
-1.19
x
|
-2.47
x
|
-0.89
x
|
-1.34
x
|
-0.4
x
|
-0.53
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
63.9
x
|
7.98
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
63.9
x
|
7.98
x
|
EV / EBITDA
|
-1,173,307
x
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
2.73
x
|
1.79
x
|
2.38
x
|
-
|
-
|
Nbr of stocks (in thousands)
|
376
|
1,682
|
2,108
|
3,159
|
8,455
|
70,273
|
-
|
Reference price
2 |
33.60
|
15.00
|
13.84
|
4.070
|
2.120
|
0.0909
|
0.0909
|
Announcement Date
|
3/26/20
|
3/25/21
|
3/30/22
|
3/14/23
|
3/28/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
0.1
|
0.8
|
EBITDA
|
-10.76
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-10.84
|
-11.5
|
-11.5
|
-13.16
|
-10.52
|
-11.3
|
-12.1
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-11,300%
|
-1,512.5%
|
Earnings before Tax (EBT)
1 |
-13.31
|
-11.73
|
-11.23
|
-13.18
|
-10.06
|
-11.3
|
-12.1
|
Net income
1 |
-17.53
|
-12.12
|
-11.35
|
-13.18
|
-10.06
|
-11.3
|
-12.1
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-11,300%
|
-1,512.5%
|
EPS
2 |
-46.80
|
-12.60
|
-5.600
|
-4.560
|
-1.580
|
-0.2300
|
-0.1700
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/26/20
|
3/25/21
|
3/30/22
|
3/14/23
|
3/28/24
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
0.1
|
0.1
|
0.1
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-3.072
|
-2.855
|
-3.572
|
-3.417
|
-3.313
|
-2.939
|
-2.995
|
-3.129
|
-1.5
|
-2.781
|
-2.6
|
-3
|
-3
|
-3.1
|
-3.1
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-3,000%
|
-3,100%
|
-3,100%
|
Earnings before Tax (EBT)
1 |
-3.105
|
-2.858
|
-3.591
|
-3.44
|
-3.29
|
-2.943
|
-2.557
|
-3.101
|
-1.5
|
-2.776
|
-2.6
|
-3
|
-3
|
-3.1
|
-3.1
|
Net income
1 |
-3.105
|
-2.858
|
-3.591
|
-3.44
|
-3.29
|
-2.943
|
-2.557
|
-3.101
|
-1.5
|
-2.776
|
-2.6
|
-3
|
-3
|
-3.1
|
-3.1
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-3,000%
|
-3,100%
|
-3,100%
|
EPS
2 |
-1.400
|
-1.400
|
-1.200
|
-1.000
|
-0.9600
|
-0.9300
|
-0.4300
|
-0.4000
|
-0.1700
|
-0.2600
|
-0.0700
|
-0.0400
|
-0.0400
|
-0.0400
|
-0.0400
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/30/22
|
5/12/22
|
8/15/22
|
11/14/22
|
3/14/23
|
5/15/23
|
8/14/23
|
11/14/23
|
3/28/24
|
5/14/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
5.070
|
2.270
|
0.8900
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.04
|
-
|
0.05
|
0.2
|
0.03
|
0.1
|
0.2
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
100%
|
25%
|
Announcement Date
|
3/26/20
|
3/25/21
|
3/30/22
|
3/14/23
|
3/28/24
|
-
|
-
|
Last Close Price
0.0909
USD Average target price
8
USD Spread / Average Target +8,700.88% Consensus |
1st Jan change
|
Capi.
|
---|
| -95.71% | 6.39M | | +18.97% | 45.34B | | +41.98% | 40.42B | | -10.06% | 37.92B | | +31.15% | 31.75B | | -7.79% | 27.71B | | +13.32% | 26.52B | | +43.05% | 13.96B | | +31.28% | 12.44B | | -7.41% | 11.26B |
Other Biotechnology & Medical Research
|